OncoCyte Yönetim

Yönetim kriter kontrolleri 1/4

Şu anda CEO hakkında yeterli bilgiye sahip değiliz.

Anahtar bilgiler

Josh Riggs

İcra Kurulu Başkanı

US$514.1k

Toplam tazminat

CEO maaş yüzdesi	47.1%
CEO görev süresi	less than a year
CEO sahipliği	n/a
Yönetim ortalama görev süresi	less than a year
Yönetim Kurulu ortalama görev süresi	2.8yrs

Son yönetim güncellemeleri

Recent updates

CEO Tazminat Analizi

Josh Riggs'un ücretlendirmesi OncoCyte'un kazancına kıyasla nasıl değişti?
Tarih	Toplam Tazminat	Maaş	Şirket Kazançları
Jun 30 2023	n/a	n/a	-US$17m
Mar 31 2023	n/a	n/a	-US$11m
Dec 31 2022	US$514k	US$242k	-US$19m

Tazminat ve Piyasa: Josh 'ın toplam tazminatı ($USD 514.11K ) German pazarındaki benzer büyüklükteki şirketler için ortalamadır ($USD 475.63K ).

Tazminat ve Kazançlar: Josh şirketinin tazminatını şirket performansıyla karşılaştırmak için yeterli veri yok.

CEO

Josh Riggs (40 yo)

less than a year

Görev süresi

US$514,110

Tazminat

Mr. Joshua Riggs, also known as Josh, serves as Director of OncoCyte Corporation since February 28, 2023, serves as its Chief Executive Officer & President since February 24, 2023. He served as Interim Chi...

Liderlik Ekibi

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Joshua Riggs	President	less than a year	US$514.11k	Veri yok
James Liu	Senior Director	1.1yrs	US$259.74k	0% € 0
Ekkehard Schutz	Chief Science Officer	less than a year	Veri yok	Veri yok
Yuh-Min Chiang	Senior Vice President of R&D and Product Development	no data	Veri yok	Veri yok
Sandra O'Donald	Senior Vice President of Business Operations	less than a year	Veri yok	Veri yok
Michael West	Scientific Advisor	8yrs	US$328.84k	Veri yok
Peter Hong	Secretary	no data	Veri yok	Veri yok
Sara Riordan	Director of Medical Education	no data	Veri yok	Veri yok

0.8yrs

Ortalama Görev Süresi

40yo

Ortalama Yaş

Deneyimli Yönetim: 7OC0 'un yönetim ekibi deneyimli olarak kabul edilmiyor ( 0.8 yıl), bu da yeni bir ekibin varlığını gösteriyor.

Yönetim Kurulu Üyeleri

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Joshua Riggs	President	less than a year	US$514.11k	Veri yok
Louis Silverman	Lead Independent Director	less than a year	US$17.30k	0.000040% € 8.6
Andrew Arno	Independent Chairman	8.3yrs	US$125.01k	0.59% € 127.1k
Alfred Kingsley	Independent Director	14.1yrs	US$118.50k	0.28% € 59.8k
Daniel Hayes	Member of Scientific & Medical Advisory Board	2.8yrs	Veri yok	Veri yok
David R. Gandara	Member of Scientific & Medical Advisory Board	no data	Veri yok	Veri yok
Robert Ferris	Member of Scientific & Medical Advisory Board	no data	Veri yok	Veri yok
John Kirkwood	Member of Scientific & Medical Advisory Board	2.8yrs	Veri yok	Veri yok
Andrew Last	Independent Director	7.8yrs	US$118.00k	0.037% € 7.8k
Fred Hirsch	Member of Scientific & Medical Advisory Board	2.8yrs	Veri yok	Veri yok
Heinz-Josef Lenz	Member of Scientific & Medical Advisory Board	2.8yrs	Veri yok	Veri yok
Ignacio Wistuba	Member of Scientific & Medical Advisory Board	2.8yrs	Veri yok	Veri yok

2.8yrs

Ortalama Görev Süresi

64yo

Ortalama Yaş

Deneyimli Yönetim Kurulu: 7OC0 'nin yönetim kurulu üyeleri deneyimli olarak kabul edilmiyor ( 2.8 yıllık ortalama görev süresi), bu da yeni bir yönetim kurulu olduğunu gösteriyor.

OncoCyte Yönetim

Yönetim kriter kontrolleri 1/4

Anahtar bilgiler

Son yönetim güncellemeleri

OncoCyte Corporation Appoints Andrea James as Chief Financial Officer

OncoCyte Corporation, Annual General Meeting, Jun 28, 2024

Oncocyte Corporation Announces Executive Changes

Jennifer Levin Carter and John Peter Gutfreund Not to Stand for Re-Election to the Board of Directors of OncoCyte Corporation

OncoCyte Corporation, Annual General Meeting, Jun 23, 2023

OncoCyte Corporation Announces Executive Changes

Recent updates

OncoCyte Corporation to Report Q3, 2024 Results on Nov 12, 2024

Oncocyte's DetermaIO Immuno-Oncology Assay Predicts Response to Atezolizumab in Phase 2 Clinical Trial

OncoCyte Corporation announced that it expects to receive $10.203435 million in funding from Bio-Rad Laboratories, Inc.

OncoCyte Corporation has completed a Follow-on Equity Offering in the amount of $0.316184 million.

OncoCyte Corporation has filed a Follow-on Equity Offering in the amount of $7.5 million.

OncoCyte Corporation to Report Q2, 2024 Results on Aug 08, 2024

Oncocyte Announces Notice of Prior Non-Compliance and Subsequent Compliance with Nasdaq Listing Rules 5605(b)(1) and 5605(c)(2)

OncoCyte Corporation announced that it expects to receive $3.5 million in funding from Bio-Rad Laboratories, Inc.

OncoCyte Corporation Appoints Andrea James as Chief Financial Officer

Oncocyte Corporation Announces Promising Results in A Phase 2 Clinical Trial

Oncocyte Corporation Announces Favorable Oncocyte Vitgraft Kidney Study Results

OncoCyte Corporation to Report Q1, 2024 Results on May 15, 2024

OncoCyte Corporation, Annual General Meeting, Jun 28, 2024

OncoCyte Corporation announced that it has received $15.8 million in funding

Broadwood Capital, Inc. Engages with OncoCyte Corporation

OncoCyte Corporation announced that it expects to receive $15.8 million in funding

OncoCyte Corporation announced delayed annual 10-K filing

Oncocyte Corporation Begins FDA Submissions Process for VitaGraft Transplant Assays

OncoCyte Corporation to Report Q3, 2023 Results on Nov 09, 2023

Oncocyte Corporation Announces Vitagraft Kidney Transplant Diagnostic Test Receives Cms Coverage

Oncocyte Corporation Announces Executive Changes

OncoCyte Regains Compliance with Nasdaq Listing Requirements

OncoCyte Corporation to Report Q2, 2023 Results on Aug 10, 2023

Oncocyte Corporation Announces the Publication of New Data Demonstrating Vitagraft Kidney's Novel Ability to Help Physicians Treat Kidney Transplant Patients

Oncocyte Announces 1-For-20 Reverse Stock Split to Regain Compliance with Minimum Bid Price Requirement

Jennifer Levin Carter and John Peter Gutfreund Not to Stand for Re-Election to the Board of Directors of OncoCyte Corporation

OncoCyte Corporation, Annual General Meeting, Jun 23, 2023

OncoCyte Receives Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard

Oncocyte Applies to Transfer the Listing of its Common Stock from The Nasdaq Global Market to The Nasdaq Capital Market

OncoCyte Corporation Announces Reduction of Workforce

OncoCyte Corporation Announces Executive Changes

Melinda Griffith Notifies Oncocyte Corporation F Her Resignation from the Board, Effective January 1, 2023

Third quarter 2022 earnings released: US$0.081 loss per share (vs US$0.15 loss in 3Q 2021)

High number of new directors

Third quarter 2022 earnings released: US$0.079 loss per share (vs US$0.15 loss in 3Q 2021)

OncoCyte Corporation to Report Q3, 2022 Results on Nov 10, 2022

Oncocyte Corporation Appoints James Liu as Controller and Principal Accounting Officer

Oncocyte Announces Unanimous Recommendation from the Advisory Panel for Clinical Diagnostic Laboratory Tests on Determarx to CMS

Oncocyte Announces Publication of the Validation of DetermaIO in Predicting Immune Therapy Response in Metastatic Bladder Cancer

Independent Chairman recently bought €142k worth of stock

OncoCyte Corporation Receives Non-Compliance Letter from Nasdaq

Second quarter 2022 earnings released: US$0.073 loss per share (vs US$0.12 loss in 2Q 2021)

OncoCyte Corporation Appoints Anish John as Chief Financial Officer

OncoCyte Corporation Announces the Appointment of John Peter Gutfreund as Independent Member of its Board of Directors

OncoCyte Corporation to Report Q2, 2022 Results on Aug 10, 2022

OncoCyte Corporation Announces Resignation of Li Yu as Controller and Principal Accounting Officer

OncoCyte Corporation(NasdaqGM:OCX) dropped from Russell 2000 Dynamic Index

OncoCyte Corporation, Annual General Meeting, Jul 15, 2022

First quarter 2022 earnings released: US$0.11 loss per share (vs US$0.048 loss in 1Q 2021)

Oncocyte Corporation Completes Validation of TheraSure™ Transplant Monitor Test

High number of new directors

Broadwood Capital Engages in Discussions with OncoCyte Corporation

OncoCyte Corporation has completed a Follow-on Equity Offering in the amount of $35.000001 million.

Full year 2021 earnings: Revenues and EPS in line with analyst expectations

OncoCyte Corporation to Report Q4, 2021 Results on Mar 10, 2022

OncoCyte Corporation Announces Peer-Reviewed Publication in Cancers Showing Utility of DetermaCNI™ Blood-Only Monitoring Test to Detect Recurrence Following Surgery in Epithelial Ovarian Cancer

Oncocyte Corporation Announces Results from DetermaIO™ Test

Third quarter 2021 earnings released: US$0.15 loss per share (vs US$0.10 loss in 3Q 2020)

Broadwood Partners Engages in Discussions with OncoCyte Corporation

Oncocyte Corporation Announces Oral Presentation of New Data on Its DetermaIO Immunotherapy Response Test at the European Society for Medical Oncology Annual Meeting

Oncocyte Corporation Launches Nationwide, Prospective, Real-World Registry for Patients with Potentially Curable Early-Stage Lung Cancer

Second quarter 2021 earnings released: US$0.12 loss per share (vs US$0.14 loss in 2Q 2020)

Forecast to breakeven in 2024

First quarter 2021 earnings released: US$0.048 loss per share (vs US$0.13 loss in 1Q 2020)

CEO, President & Director recently bought €44k worth of stock

OncoCyte Corporation Announces Peer-Reviewed Publication of Data Assessing Use of DetermaIO™ to Identify Patients Likely to Benefit from Immunotherapy Across Multiple Tumor Types

Oncocyte Corporation Announces Formation of Medical Advisory Board

Oncocyte Corporation Announces Agreement with MultiPlan Network, Expanding Patient Access to Determarx™

OncoCyte Corporation to Report Q4, 2020 Results on Mar 16, 2021